Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn Henry

Showing results (171-180 of 195) with videos related to

Pageof 20
Sort By:
Technology in Cancer Research & Treatment|September 29, 2022
A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study ProtocolAnukriti Sharma, Ken B Johnson, Bihua Bie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2017
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202N Lynn Henry, Joseph M Unger, Anne F Schott, et al.
Breast Cancer Research and Treatment|February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifenStephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
JAMA Oncology|December 17, 2020
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With CancerCatherine H Van Poznak, Joseph M Unger, Amy K Darke, et al.
Molecular Cell|July 24, 2012
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell populationHasan Korkaya, Gwang-Il Kim, April Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2020
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105Dawn L Hershman, Joseph M Unger, Grace Clarke Hillyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Pageof 20

Showing results (171-180 of 195) with videos related to

Sort By:
Pageof 20
Technology in Cancer Research & Treatment|September 29, 2022
A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study ProtocolAnukriti Sharma, Ken B Johnson, Bihua Bie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2017
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202N Lynn Henry, Joseph M Unger, Anne F Schott, et al.
Breast Cancer Research and Treatment|February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifenStephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
JAMA Oncology|December 17, 2020
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With CancerCatherine H Van Poznak, Joseph M Unger, Amy K Darke, et al.
Molecular Cell|July 24, 2012
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell populationHasan Korkaya, Gwang-Il Kim, April Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2020
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105Dawn L Hershman, Joseph M Unger, Grace Clarke Hillyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Pageof 20